Cure8 trial brief
This trial is testing duvakitug as a maintenance treatment for people with moderately to severely active ulcerative colitis who responded to an earlier study, which could expand treatment options if later shown to be safe and effective.
Adults (and eligible older adolescents) with moderate–severe ulcerative colitis, clinicians treating UC, and researchers following new maintenance therapies or drug development.
This ClinicalTrials.gov record describes a Phase 3, randomized, double‑blind, placebo‑controlled maintenance study of duvakitug given by subcutaneous injection in adults (and some older adolescents where permitted) with moderately to severely active ulcerative colitis who responded in the parent induction study (SUNSCAPE‑1).
The pivotal maintenance sub‑study runs 40 weeks with a separate open‑label extension of up to 240 weeks; planned enrollment is 671 participants and the primary endpoint is clinical remission by a modified Mayo Score at Week 40.
The record lists three duvakitug dose arms plus placebo and includes typical trial inclusion/exclusion notes and trial sites in the United States. This is a trial registration record (recruiting) and does not report results or safety outcomes here.
If you are considering participation or want results, check the trial record for contact details and look for future updates or publications reporting efficacy and safety data.
This is a trial registration (Phase 3, recruiting) and does not contain trial results. The study population is participants who achieved response in a prior induction study (SUNSCAPE‑1); eligibility, dosing, and endpoints are defined in the record. Consult trial contacts or peer‑reviewed publications for results when available.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
